Carlsmed (CARL) Q4 2025 earnings review
Top-Line Scaling Shows Deceleration While Operating Losses Widen
Carlsmed delivered a robust Q4 with revenue up 61% year-over-year to $15.2M, alongside impressive gross margin expansion to 76.5%. However, the company is transitioning out of its hyper-growth phase. Revenue growth decelerated sharply from nearly 100% in Q2 and Q3 down to 61% this quarter, and FY26 guidance implies a further slowdown to 44%. Meanwhile, heavy investments in sales and marketing to support commercial launches have caused net losses to widen by 82% YoY to $8.6M. The recent July 2025 IPO leaves the balance sheet flush with $109.9M in cash, providing ample runway, but the divergence between slowing top-line momentum and accelerating cash burn requires close monitoring.
🐂 Bull Case
Gross margins expanded from 73.4% in Q2 to 76.5% in Q4 as production bottlenecks and expedite fees were resolved. At the same time, lead times were cut to under six business days, showing excellent operational leverage.
Newly published 2-year data in the Global Spine Journal shows a 74% reduction in revision rates for aprevo lumbar patients. This provides sales reps with highly compelling, peer-reviewed ammunition to drive hospital adoption.
🐻 Bear Case
While 61% growth is objectively strong, it marks a significant deceleration from the 98% seen just a quarter ago. FY26 guidance of 44% growth suggests the easiest market share gains have already been captured.
Despite a stellar 76.5% gross margin, aggressive Sales & Marketing spend ($10.8M in Q4) is consuming nearly all gross profits ($11.6M). Total operating expenses doubled YoY, leading to worsening EBITDA losses.
⚖️ Verdict: ⚪
Neutral. Carlsmed has a differentiated, high-margin product with a strong cash cushion. However, the rapidly decelerating growth rate combined with accelerating operating expenses presents a classic 'show-me' story for the upcoming cervical launch.
Key Themes
Sales & Marketing Spend Outpacing Gross Profit Growth
A concerning trend is emerging in the cost structure. Sales and marketing expenses surged to $10.8M in Q4, up 69% YoY. While gross profits are growing beautifully (up 65% YoY), the relentless increase in S&M and G&A spend means the company is not yet achieving operating leverage. S&M expense as a percentage of revenue remains elevated at 71%, indicating high customer acquisition costs.
aprevo Cervical Launch and NTAP Reimbursement
The successful commercial launch of the aprevo cervical system represents the most critical growth driver for FY26. Bolstering this rollout is the CMS New Technology Add-On Payment (NTAP) reimbursement which went into effect on October 1, 2025. This removes a significant financial friction point for hospital adoption.
Manufacturing Efficiencies Accelerating Gross Margins
Management successfully resolved the manufacturing bottlenecks that plagued the first half of the year. In Q2, expedite production fees dragged gross margins down to 73.4%. By Q4, margins accelerated to a record 76.5%, and lead times shrank to within six business days—a crucial logistical advantage for surgeon adoption.
Software Ecosystem Expansion
The launch of the myaprevo ecosystem for browser and mobile integration signals a strategic shift from being purely a hardware/implant provider to an integrated digital health platform. This should improve surgeon stickiness and streamline the pre-operative planning workflow.
Other KPIs
Stable. Following the July 2025 IPO which netted $93.5M, the balance sheet is well-capitalized. The company burned approximately $5.4M in cash sequentially from Q3 ($115.3M), providing a comfortable multi-year runway even if current burn rates persist.
Decelerating. Losses widened sequentially from $(8.2)M in Q3 and heavily compared to $(4.6)M a year ago. The company adds back stock-based compensation ($0.8M), which jumped 690% YoY as a newly public entity, but the core cash burn from operations is objectively increasing.
Guidance
Decelerating. The midpoint of $72.5M implies a 44% year-over-year growth rate. While healthy in absolute terms, it represents a sharp slowdown from the 86% growth achieved in FY25. Achievement of the upper end of this range will likely depend heavily on the adoption curve of the newly launched aprevo cervical system.
Key Questions
Path to Operating Leverage
Sales and marketing expenses consumed 71% of revenue in Q4. What is the target S&M percentage for FY26, and at what revenue run-rate do you expect to see meaningful operating leverage materialize?
aprevo Cervical Cannibalization vs Expansion
With the aprevo cervical launch underway, are you seeing existing lumbar surgeons adopt the cervical product, or is it primarily opening doors to net-new surgeon accounts?
Growth Deceleration Drivers
FY26 revenue guidance implies 44% growth, down from 86% in FY25. Is this deceleration purely a function of the law of large numbers, or are you experiencing lengthening sales cycles or hospital capital constraints?